Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF

J Card Fail. 2024 Apr;30(4):610-612. doi: 10.1016/j.cardfail.2024.01.005. Epub 2024 Feb 1.

Authors

Elissa Driggin¹, Parag Goyal²

Affiliations

¹ Department of Medicine, Columbia University, New York, NY.
² Program for the Care and Study of the Aging Heart, Department of Medicine, Weill Cornell Medicine, New York, NY. Electronic address: pag9051@med.cornell.edu.

PMID: 38301742
DOI: 10.1016/j.cardfail.2024.01.005

No abstract available

MeSH terms

Glucagon-Like Peptide-1 Receptor Agonists* / adverse effects
Glucagon-Like Peptide-1 Receptor Agonists* / therapeutic use
Heart Failure* / complications
Heart Failure* / etiology
Humans
Malnutrition* / chemically induced
Obesity / drug therapy
Sarcopenia* / chemically induced
Stroke Volume

Substances

Glucagon-Like Peptide-1 Receptor Agonists

Grants and funding